ConvaTec Group (LON:CTEC) Price Target Raised to GBX 340

ConvaTec Group (LON:CTEC) had its price objective upped by Berenberg Bank from GBX 330 to GBX 340 in a research report report published on Thursday morning, MarketBeat.com reports. Berenberg Bank currently has a buy rating on the stock.

A number of other brokerages have also recently weighed in on CTEC. Peel Hunt reiterated an “add” rating and issued a GBX 270 target price on shares of ConvaTec Group in a report on Thursday, November 13th. JPMorgan Chase & Co. restated an “overweight” rating on shares of ConvaTec Group in a research note on Friday, November 14th. Finally, UBS Group reissued a “buy” rating and issued a GBX 375 target price on shares of ConvaTec Group in a research report on Friday, November 7th. Six analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of GBX 320.33.

ConvaTec Group Trading Down 1.1%

Shares of ConvaTec Group stock opened at GBX 234 on Thursday. The company has a debt-to-equity ratio of 85.32, a current ratio of 2.26 and a quick ratio of 0.96. The stock has a market cap of £4.56 billion, a P/E ratio of 22.08, a P/E/G ratio of 0.93 and a beta of 0.64. ConvaTec Group has a 1-year low of GBX 219.80 and a 1-year high of GBX 311.20. The stock’s 50 day simple moving average is GBX 236.08 and its 200-day simple moving average is GBX 237.62.

About ConvaTec Group

ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer.